Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 in noninfectious uveitis
2011-001243-67Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of secukinumab in uveitis, Hyalitis, posterior uveitis and 1 more (5 arms), sponsored by Novartis. Primary endpoints: Clinically significant reduction in severity of uveitis in the study eye and Safety and tolerability of intravenous secukinumab. Started Apr 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
uveitisHyalitisposterior uveitispanuveitis
Beyond the preview
Go deeper on 2011-001243-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001243-67.